The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Biomarkers of progression and risk stratification in asymptomatic Waldenström’s macroglobulinemia
Mark Bustoros, MD, Weill Cornell Medicine, New York City, NY, discusses four biomarkers associated with an increased risk of disease progression in patients with asymptomatic Waldenström’s macroglobulinemia (WM). Dr Bustoros elaborates on a calculator that has been developed and integrates these independent risk factors, allowing patients to be risk stratified into various categories. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
